Circulation:奎尼丁与多态性室性心动过速

2019-05-19 QQ MedSci原创

在无器质性心脏病(主要为特发性室颤和Brugada综合征)和急性WT段抬高型心肌梗死患者中,无QT延长的多态性室性心动过速(VT)有很好的描述。Sami Viskin等人回顾性研究发现多态性VT患者与冠状动脉疾病相关,但无急性心肌缺血的证据。研究人员筛查出43位患者在非复杂性心肌梗死或冠脉搭桥术后后几天内出现多型性VT。多态性VT均由短(364±36ms)耦合间期的额外收缩所触发。23例(53%)

在无器质性心脏病(主要为特发性室颤和Brugada综合征)和急性WT段抬高型心肌梗死患者中,无QT延长的多态性室性心动过速(VT)有很好的描述。

Sami Viskin等人回顾性研究发现多态性VT患者与冠状动脉疾病相关,但无急性心肌缺血的证据。

研究人员筛查出43位患者在非复杂性心肌梗死或冠脉搭桥术后后几天内出现多型性VT。多态性VT均由短(364±36ms)耦合间期的额外收缩所触发。23例(53%)患者发生心律不齐风暴(4-16次多型性VT恶化成室颤)。传统的抗心律不齐疗法难以逆转心律不齐风暴,包括静脉注射胺碘酮,但奎尼丁治疗有效。心律不齐风暴患者的院内死亡率高达17%。奎尼丁治疗的患者均活着出院。在长期的随访过程中(5.6±6年,范围:1个月-18年),未采用奎尼丁治疗的患者中有3位(16%)复发多态性VT。在奎尼丁治疗期间,无复发心律不齐。

奎尼丁可有效治疗对其他抗心律失常药物无反应的发生心律不齐风暴和复发性多型性VT的冠心病患者。

原始出处:

Sami Viskin,et al.Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease. Circulation. 14 May 2019. https://doi.org/10.1161/CIRCULATIONAHA.118.038036.

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1407860, encodeId=b7cb140e860d3, content=<a href='/topic/show?id=75f34622831' target=_blank style='color:#2F92EE;'>#室性心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46228, encryptionId=75f34622831, topicName=室性心动过速)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19932732764, createdName=kalseyzl, createdTime=Tue May 21 04:55:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471123, encodeId=fc6314e11236d, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Tue May 21 04:55:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629279, encodeId=d4ff16292e9f4, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue May 21 04:55:00 CST 2019, time=2019-05-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1407860, encodeId=b7cb140e860d3, content=<a href='/topic/show?id=75f34622831' target=_blank style='color:#2F92EE;'>#室性心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46228, encryptionId=75f34622831, topicName=室性心动过速)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19932732764, createdName=kalseyzl, createdTime=Tue May 21 04:55:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471123, encodeId=fc6314e11236d, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Tue May 21 04:55:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629279, encodeId=d4ff16292e9f4, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue May 21 04:55:00 CST 2019, time=2019-05-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1407860, encodeId=b7cb140e860d3, content=<a href='/topic/show?id=75f34622831' target=_blank style='color:#2F92EE;'>#室性心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46228, encryptionId=75f34622831, topicName=室性心动过速)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19932732764, createdName=kalseyzl, createdTime=Tue May 21 04:55:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471123, encodeId=fc6314e11236d, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Tue May 21 04:55:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629279, encodeId=d4ff16292e9f4, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue May 21 04:55:00 CST 2019, time=2019-05-21, status=1, ipAttribution=)]
    2019-05-21 xzw120

相关资讯

Neurology:KCNT1相关严重早发性癫痫的临床和分子特征

功能获得性KCNT1致病性突变可导致婴儿早发性严重局灶性癫痫,疾病机理研究表明奎尼丁对疾病具有潜在的治疗作用

JAMA:氢溴酸右美沙芬+硫酸奎尼丁治疗阿尔茨海默症的耐受性良好

在阿尔茨海默症患者中,躁动的现象是很常见的,但目前缺乏安全、有效的治疗方法。该研究的目的是评估氢溴酸右美沙芬-硫酸奎尼丁治疗和阿尔茨海默病有关躁动的有效性,安全性和耐受性。该项2阶段随机,多中心,双盲,安慰剂对照试验使用了一个连续的横向对比设计,2个连续5周的治疗阶段,该试验在2012年8月至 2014年8月进行。参与者为可能的阿尔茨海默病患者,临床上有显著躁动症状(临床整体印象,严重躁动得分≥4